Bedrijfsoverzicht
Pelthos Therapeutics Inc. is a bio-pharmaceutical entity dedicated to developing and commercializing therapeutic products designed to address unmet treatment needs for patients. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, where its primary objective is to advance novel therapies that tackle complex medical challenges. Its current scale is defined by a market capitalization of $75.77M, an annualized revenue of $16.80M, and an operational workforce comprising 92 employees. These financial figures indicate that the company functions as a mid-sized biotechnology firm with a significant valuation relative to its current revenue stream, suggesting that the market places a high premium on its pipeline of potential future therapies rather than current profitability. The disparity between its market cap and its revenue of $16.80M highlights that investors are pricing in substantial future growth potential, which is typical for early-stage biopharma companies that have not yet generated consistent net income.
Financiële gezondheid
Pelthos Therapeutics reported a trailing twelve-month revenue of $16.80M, yet it recorded a net income of -$43,319,000 and an EBITDA of -$29,123,000, revealing a cost structure where operational expenses significantly outweigh generated revenue. The company's free cash flow stands at -$24,652,500, which indicates a continuous burn rate that limits immediate financial flexibility and necessitates reliance on external capital or existing cash reserves to fund operations. The gross margin is recorded at 68.9%, while the operating margin is -127.8% and the profit margin is -257.9%, illustrating that while the cost of goods sold is managed efficiently, overall operational losses and non-operating costs are driving the company deep into the red. On the balance sheet, the company holds $17.97M in cash against $34.83M in debt, resulting in a debt-to-equity ratio of 89.58, which characterizes a highly leveraged financial position typical for capital-intensive biotechnology development. The current ratio of 2.06 suggests that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a layer of liquidity security despite the heavy debt load. Furthermore, the return on equity is -239.6% and the return on assets is -29.8%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common but risky phase in the development lifecycle of biopharmaceutical assets.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A, while the forward P/E is listed as -215.05, implying that the market does not expect near-term earnings growth but rather anticipates a return to profitability in the future to justify the current stock price. The price-to-book ratio is 1.88, indicating that the market is valuing the company at a significant premium of 88% over its net asset value, reflecting confidence in the intangible value of its drug pipeline. Alternative valuation metrics such as the price-to-sales ratio of 4.51 and the EV/EBITDA of -3.18 suggest that investors are focusing heavily on revenue generation potential rather than current earnings power. The stock has traded between a 52-week low of $9.00 and a 52-week high of $54.29, meaning the current market price sits within a wide volatility range that reflects high speculative risk associated with unproven therapies. The beta value of 3.99 indicates that the stock price is nearly four times more volatile than the broader market, meaning that price fluctuations will be much more pronounced during periods of market uncertainty or shifts in investor sentiment regarding biotechnology sectors.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that there is no comparable prior period data available to calculate growth rates or that the company recently entered a reporting period where such comparisons are not yet established. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available earnings—or in this case, utilizing cash reserves—directly into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment approach is standard for biotechnology firms in the development stage, where capital is required to advance clinical trials and secure regulatory approvals before the company can generate sustainable profits. The overall growth and income profile is defined by a complete absence of current income generation and a reliance on market capitalization and cash reserves to fuel future expansion, creating a high-risk, high-reward scenario dependent on the successful execution of its therapeutic pipeline.